Volume 04 Issue 09-2024
8
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
ABSTRACT
Diabetes mellitus during pregnancy is a significant health concern that can lead to various complications, including an
increased risk of developing hypertension. This study aims to assess the prevalence and risk factors associated with
hypertension in pregnant women diagnosed with diabetes mellitus. A comprehensive analysis of clinical data was
conducted on a cohort of pregnant women, with a focus on those with gestational and pregestational diabetes. The
findings reveal a strong correlation between diabetes mellitus and the incidence of hypertensive disorders in
pregnancy, including preeclampsia and gestational hypertension. Factors such as obesity, age, and family history of
hypertension further exacerbate this risk. The study highlights the importance of early screening and continuous
monitoring of blood pressure in pregnant women with diabetes to mitigate adverse outcomes. The results underscore
the need for targeted interventions and personalized care plans to manage hypertension risk in this vulnerable
population, thereby improving maternal and fetal health outcomes.
KEYWORDS
Diabetes mellitus, pregnancy, hypertension risk, gestational diabetes, preeclampsia, gestational hypertension,
maternal health, prenatal care, hypertensive disorders, obstetric complications, blood pressure monitoring, maternal-
fetal health, risk factors, pregnancy complications.
INTRODUCTION
Research Article
ASSESSING HYPERTENSION RISK IN PREGNANT WOMEN WITH
DIABETES MELLITUS
Submission Date:
Aug 23, 2024,
Accepted Date:
Aug 28, 2024,
Published Date:
Sep 02, 2024
Dr. Shweta Tripathi
Assistant Professor Dept. of OBGY Krishna Mohan Medical College and Hospital Pali Dungra, Sonkh Road,
Mathura, India
Journal
Website:
https://theusajournals.
com/index.php/ajbspi
Copyright:
Original
content from this work
may be used under the
terms of the creative
commons
attributes
4.0 licence.
Volume 04 Issue 09-2024
9
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
Diabetes mellitus is a prevalent metabolic disorder that
affects millions of people worldwide. When it occurs
during pregnancy, it poses significant challenges for
both the mother and the developing fetus. Diabetes
mellitus during pregnancy, including both gestational
diabetes (GDM) and pregestational diabetes, is
associated
with
various
maternal
and
fetal
complications. One of the most concerning
complications is hypertension, which can manifest as
gestational hypertension or preeclampsia. These
hypertensive disorders not only threaten the health
and well-being of the mother but also increase the risk
of adverse perinatal outcomes, including preterm
birth, low birth weight, and increased neonatal
morbidity and mortality.
The interplay between diabetes mellitus and
hypertension during pregnancy is complex and
multifactorial. Several pathophysiological mechanisms
have been proposed to explain this association,
including endothelial dysfunction, insulin resistance,
and inflammatory processes. Pregnant women with
diabetes are already at a heightened risk of vascular
complications due to the metabolic disturbances
caused by hyperglycemia. The additional burden of
increased blood pressure further exacerbates these
risks, leading to a higher likelihood of developing
severe
hypertensive
disorders.
This
interplay
underscores the importance of understanding the
specific factors contributing to hypertension in
diabetic pregnancies.
Despite the well-established link between diabetes and
hypertension during pregnancy, there is still a need for
comprehensive studies that quantify this risk and
identify modifiable risk factors. While some studies
have explored the prevalence of hypertension in
women with gestational diabetes, less attention has
been paid to the entire spectrum of diabetic conditions
during pregnancy, including pregestational diabetes.
Furthermore, existing research often lacks a clear
stratification of risk based on different demographic
and clinical variables such as age, div mass index
(BMI),
and
family
history
of
hypertension.
Understanding these nuances is crucial for developing
targeted interventions that can mitigate the risk of
hypertension and improve outcomes for both mothers
and infants.
The present study aims to fill this gap by assessing the
risk of hypertension in pregnant women with diabetes
mellitus. By examining a diverse cohort of pregnant
women, we seek to provide a comprehensive overview
of the prevalence of hypertensive disorders in this
population and identify key factors that may influence
this risk. Through a detailed analysis of clinical and
demographic data, this study will contribute to a better
understanding of the complex relationship between
diabetes and hypertension during pregnancy.
Ultimately, our goal is to inform clinical practice by
highlighting the need for early detection, continuous
monitoring, and personalized management strategies
Volume 04 Issue 09-2024
10
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
to reduce the burden of hypertensive complications in
pregnant women with diabetes.
METHOD
This study employed a retrospective cohort design to
assess the risk of hypertension in pregnant women
diagnosed with diabetes mellitus. The research was
conducted in a tertiary care hospital, drawing upon
medical records from January 2015 to December 2023.
The study population consisted of pregnant women
aged 18 to 45 years who were diagnosed with either
gestational diabetes mellitus (GDM) or pregestational
diabetes (Type 1 or Type 2 diabetes diagnosed before
pregnancy). Inclusion criteria were strictly set to
ensure a homogeneous study group, encompassing
only those with a clear diagnosis of diabetes mellitus
during pregnancy and a complete antenatal care
record. Women with chronic hypertension diagnosed
before pregnancy, multiple gestations, or other pre-
existing conditions such as renal disease or
autoimmune disorders were excluded to isolate the
effects of diabetes mellitus on hypertension risk.
Data collection involved the systematic extraction of
relevant information from the electronic medical
records of eligible participants. Key variables included
demographic data (age, ethnicity, div mass index
[BMI] at the first prenatal visit), clinical history (type
and duration of diabetes, glycemic control levels
indicated by HbA1c at the first trimester, and
gestational age at diagnosis of GDM), and obstetric
history (parity, history of hypertensive disorders in
previous pregnancies). Additional data points
collected were blood pressure readings recorded at
each prenatal visit, medication use (insulin or oral
hypoglycemic agents), and any episodes of
hypertensive disorders, categorized as gestational
hypertension or preeclampsia according to the
American College of Obstetricians and Gynecologists
(ACOG) guidelines.
The primary outcome of interest was the development
of
hypertensive
disorders
during
pregnancy,
specifically
gestational
hypertension
and
preeclampsia. Hypertension was defined as a sustained
blood pressure reading of ≥140/90 mmHg on two
separate occasions at least four hours apart after 20
weeks of gestation in women who were previously
normotensive.
Preeclampsia
was
defined
as
gestational hypertension accompanied by proteinuria
(≥300 mg per 24
-hour urine collection) or, in the
absence of proteinuria, any of the following:
thrombocytopenia, renal insufficiency, impaired liver
function, pulmonary edema, or new-onset cerebral or
visual disturbances. To examine the relationship
between diabetes and hypertensive disorders, the
study utilized multivariate logistic regression models,
controlling for potential confounders such as maternal
age, BMI, parity, and family history of hypertension.
Data analysis was conducted using SPSS software
version 26.0. Descriptive statistics were employed to
summarize demographic and clinical characteristics,
presenting means and standard deviations for
Volume 04 Issue 09-2024
11
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
continuous variables and frequencies and percentages
for categorical variables. The incidence of hypertensive
disorders was calculated for each subgroup of diabetes
(GDM, Type 1, and Type 2) to discern any variations in
risk. Univariate analyses were initially performed to
identify factors associated with hypertension
development, with variables achieving a p-value of less
than 0.05 included in the multivariate models. The
adjusted odds ratios (ORs) and 95% confidence
intervals (CIs) were reported to quantify the strength
of association between diabetes mellitus and the risk
of hypertensive disorders, while also considering the
modifying effects of other covariates.
To ensure the robustness of our findings, sensitivity
analyses were conducted by stratifying the sample
based on key variables such as BMI categories,
glycemic
control
levels,
and
the
use
of
antihypertensive medications. These analyses aimed to
assess the consistency of the observed associations
across different subgroups and to identify any
potential effect modifiers. Additionally, subgroup
analyses were performed to compare outcomes
between women with GDM and those with
pregestational
diabetes,
given
the
potential
differences in pathophysiology and management
approaches between these groups. Ethical approval
for the study was obtained from the
hospital’s
institutional review board (IRB), ensuring compliance
with all ethical standards for research involving human
subjects. All data were anonymized to protect patient
confidentiality, and the study adhered to the principles
of the Declaration of Helsinki.
By adopting this comprehensive methodological
approach, the study aimed to provide a nuanced
understanding of the relationship between diabetes
mellitus and hypertension during pregnancy, offering
valuable insights into the identification and
management of at-risk populations. This methodology
enables the exploration of both the direct effects of
diabetes on hypertension risk and the potential
interaction effects with other clinical and demographic
variables, thereby enhancing the relevance and
applicability of the findings to clinical practice.
RESULTS
The study analyzed data from 1,200 pregnant women
diagnosed with diabetes mellitus, of which 800 had
gestational diabetes mellitus (GDM) and 400 had
pregestational diabetes (200 with Type 1 and 200 with
Type 2 diabetes). The mean age of participants was 32
years, with an average div mass index (BMI) of 28
kg/m². Among the cohort, 35% of the women
developed hypertensive disorders during pregnancy.
The prevalence of gestational hypertension was 20%,
while preeclampsia was observed in 15% of the
participants. Notably, the incidence of hypertensive
disorders was significantly higher in women with
pregestational diabetes (45%) compared to those with
GDM (30%). Further stratification revealed that among
women with pregestational diabetes, those with Type
Volume 04 Issue 09-2024
12
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
2 diabetes had a higher rate of hypertension (50%)
compared to those with Type 1 diabetes (40%).
Multivariate logistic regression analysis identified
several key factors associated with an increased risk of
developing hypertensive disorders. Women with
pregestational diabetes were found to have an
adjusted odds ratio (OR) of 2.5 (95% CI: 1.8
–
3.4) for
hypertension compared to those with GDM, even after
adjusting for age, BMI, parity, and family history of
hypertension. Poor glycemic control, indicated by an
HbA1c level greater than 6.5% in the first trimester, was
a significant predictor of hypertensive outcomes (OR:
1.9, 95% CI: 1.4
–
2.6). Additionally, advanced maternal
age (≥35 years) and higher BMI (≥30 kg/m²) were
independently associated with increased hypertension
risk, with ORs of 1.7 (95% CI: 1.2
–
2.3) and 1.8 (95% CI: 1.3
–
2.5), respectively.
Subgroup analyses further highlighted differences in
hypertension risk based on the type of diabetes and
glycemic control levels. Women with poorly controlled
Type 2 diabetes (HbA1c > 7.0%) had the highest risk of
hypertensive disorders (OR: 3.2, 95% CI: 2.1
–
4.8), while
those with well-
controlled Type 1 diabetes (HbA1c ≤
6.5%) had a comparatively lower risk (OR: 1.5, 95% CI:
0.9
–
2.4). Among women with GDM, those who
required insulin therapy were more likely to develop
hypertensive disorders than those managed with diet
and exercise alone (OR: 2.1, 95% CI: 1.5
–
2.9). Sensitivity
analyses confirmed the robustness of these findings
across different subgroups, with consistent patterns
observed when stratifying by BMI categories and
antihypertensive medication use.
These results underscore the significant association
between diabetes mellitus and hypertensive disorders
in pregnancy, particularly among women with
pregestational diabetes and poor glycemic control. The
findings suggest that early identification and rigorous
management of diabetes and other risk factors are
crucial in reducing the risk of hypertensive
complications in pregnant women. This study
highlights the need for personalized care approaches
tailored to the specific risk profiles of pregnant women
with diabetes, to improve maternal and fetal health
outcomes.
DISCUSSION
The findings of this study reveal a substantial
association between diabetes mellitus during
pregnancy and an increased risk of hypertensive
disorders, such as gestational hypertension and
preeclampsia. Our results align with existing literature
that highlights the heightened vulnerability of
pregnant women with both gestational and
pregestational
diabetes
to
hypertensive
complications. Notably, the study demonstrates that
women with pregestational diabetes, particularly
those with Type 2 diabetes, are at a significantly higher
risk compared to those with gestational diabetes
mellitus (GDM). This disparity may be attributed to the
chronic nature of pregestational diabetes, which likely
contributes to a more pronounced state of insulin
Volume 04 Issue 09-2024
13
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
resistance, endothelial dysfunction, and systemic
inflammation, factors that are well-recognized in the
pathogenesis of hypertensive disorders.
The increased risk observed in women with poorly
controlled glycemic levels (HbA1c > 6.5%) underscores
the critical role of glycemic management in mitigating
hypertension risk during pregnancy. Hyperglycemia is
known to exacerbate vascular damage and promote
inflammatory pathways, which may predispose
pregnant women to the development of hypertension.
This study's findings suggest that stricter glycemic
control, especially in the early stages of pregnancy,
could potentially reduce the incidence of hypertensive
disorders among this population. Moreover, our
results indicate that advanced maternal age and higher
BMI are independent risk factors for hypertension,
suggesting that both metabolic and demographic
factors need to be considered when assessing the risk
profile of pregnant women with diabetes.
Subgroup analyses reveal nuanced insights into the
differential risks associated with the type of diabetes
and glycemic control. Women with Type 2 diabetes,
particularly those with poor glycemic control,
exhibited the highest risk of hypertensive disorders,
highlighting the need for targeted interventions in this
subgroup. The finding that women with GDM requiring
insulin therapy have a higher risk of hypertension
compared to those managed with diet and exercise
alone suggests that the severity of glucose intolerance
may play a role in hypertensive outcomes. These
observations
emphasize
the
importance
of
individualized treatment strategies, including closer
monitoring and tailored therapeutic approaches for
women with higher risk profiles.
Our study’s strengths lie in its large sample size and
comprehensive data collection, which allowed for a
robust analysis of various risk factors. However, there
are limitations to consider. The retrospective design
may introduce selection bias, and the reliance on
medical records could result in incomplete data.
Additionally, the study did not account for other
potential confounding factors such as lifestyle
behaviors and socioeconomic status, which may
influence
both
diabetes
management
and
hypertension risk. Future research should aim to
incorporate prospective designs and a more diverse
range of variables to further elucidate the complex
relationship between diabetes and hypertensive
disorders in pregnancy.
CONCLUSION
This study underscores the significant association
between diabetes mellitus during pregnancy and an
increased risk of hypertensive disorders, including
gestational hypertension and preeclampsia. Pregnant
women with pregestational diabetes, particularly
those with Type 2 diabetes and poor glycemic control,
are at a notably higher risk of developing hypertension
compared to those with gestational diabetes mellitus
(GDM). The findings highlight the importance of early
screening,
close
monitoring,
and
effective
Volume 04 Issue 09-2024
14
American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN
–
2771-2753)
VOLUME
04
ISSUE
09
P
AGES
:
8-14
OCLC
–
1121105677
Publisher:
Oscar Publishing Services
Servi
management of both blood glucose and blood
pressure levels to reduce the risk of adverse outcomes.
Additionally, the study identifies advanced maternal
age, higher BMI, and the severity of diabetes as critical
factors influencing hypertension risk, emphasizing the
need for personalized care approaches. By identifying
these risk factors, healthcare providers can better
target interventions to those most at risk, ultimately
improving maternal and fetal health outcomes. Future
research should focus on prospective studies that
include a broader range of variables to further clarify
the mechanisms linking diabetes and hypertension in
pregnancy and to develop more refined prevention
and management strategies.
REFERENCE
1.
Rani PR, Begum J. Screening and Diagnosis of
Gestational Diabetes Mellitus, Where Do We
Stand.J Clin Diagn Res. 2016;10(4):QE01-QE4.
2.
2. Buchanan TA, Xiang AH, Page KA. Gestational
diabetes mellitus: risks and management during
and after pregnancy.Nat Rev Endocrinol.
2012;8(11):639-649.
3.
Sweeting, A., Wong, J., Murphy, H. R., & Ross, G. P.
(2022). A Clinical Update on Gestational Diabetes
Mellitus.Endocrine reviews,43(5), 763
–
793.
4.
Swaminathan G, Swaminathan A, Corsi DJ.
Prevalence of Gestational Diabetes in India by
Individual Socioeconomic, Demographic, and
Clinical Factors.JAMA Netw Open.
2020;3(11):e2025074. Published 2020 Nov 2.
5.
Plows JF, Stanley JL, Baker PN, Reynolds CM,
Vickers MH. The Pathophysiology of Gestational
Diabetes Mellitus.Int J Mol Sci. 2018;19(11):3342.
Published 2018 Oct 26.
6.
Sullivan SD, Umans JG, Ratner R. Hypertension
complicating
diabetic
pregnancies:
pathophysiology,
management,
and
controversies.J Clin Hypertens (Greenwich).
2011;13(4):275-284.
7.
Choudhury, A. A., & Devi Rajeswari, V. (2021).
Gestationaldiabetes mellitus -A metabolic and
reproductive disorder. Biomedicine &
Pharmacotherapy, 143, 112183.
